NASDAQ:CYTX - Cytori Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.80 +0.15 (+9.09 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$1.65
Today's Range$1.62 - $1.86
52-Week Range$1.62 - $12.10
Volume77,190 shs
Average Volume118,315 shs
Market Capitalization$10.78 million
P/E Ratio-0.28
Dividend YieldN/A
Cytori Therapeutics logoCytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments


Debt-to-Equity RatioN/A
Current Ratio0.60
Quick Ratio0.42


Trailing P/E Ratio-0.28
Forward P/E Ratio-1.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.69 million
Price / Sales4.12
Cash FlowN/A
Price / CashN/A
Book Value$2.25 per share
Price / Book0.80


EPS (Most Recent Fiscal Year)($6.50)
Net Income$-22,680,000.00
Net Margins-428.14%
Return on Equity-190.35%
Return on Assets-65.83%


Outstanding Shares6,160,000

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics's stock reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.30. The biotechnology company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $2.43 million. Cytori Therapeutics had a negative return on equity of 190.35% and a negative net margin of 428.14%. During the same period in the prior year, the business posted ($2.40) EPS. View Cytori Therapeutics' Earnings History.

When is Cytori Therapeutics' next earnings date?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Cytori Therapeutics.

What price target have analysts set for CYTX?

4 brokerages have issued 1-year price objectives for Cytori Therapeutics' shares. Their forecasts range from $16.50 to $40.00. On average, they anticipate Cytori Therapeutics' share price to reach $25.50 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.

What are Wall Street analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (5/15/2018)
  • 2. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:
  • Dr. Marc H. Hedrick, CEO, Pres & Director (Age 55)
  • Mr. Tiago M. Girão, VP of Fin., CFO & Sec. (Age 39)
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 57)
  • Mr. Russ Havranek, VP of Global Marketing
  • Mr. John B. Ferris, Sr. Director of European Bus. Devel. Technology

Has Cytori Therapeutics been receiving favorable news coverage?

News articles about CYTX stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Cytori Therapeutics?

Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $1.80.

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $10.78 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($6.50) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]

MarketBeat Community Rating for Cytori Therapeutics (CYTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  448
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.